for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

ONO PHARMACEUTICAL CO., LTD.

4528.T

Latest Trade

2,455.50JPY

Change

16.00(+0.66%)

Volume

823,700

Today's Range

2,441.50

 - 

2,462.00

52 Week Range

1,822.00

 - 

2,702.00

As of on the Tokyo Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
2,439.50
Open
2,446.00
Volume
823,700
3M AVG Volume
33.00
Today's High
2,462.00
Today's Low
2,441.50
52 Week High
2,702.00
52 Week Low
1,822.00
Shares Out (MIL)
484.12
Market Cap (MIL)
1,288,889.00
Forward P/E
21.99
Dividend (Yield %)
1.84

Next Event

Q3 2020 Ono Pharmaceutical Co Ltd Earnings Release

Latest Developments

More

Bayer, Bristol-Myers Squibb And Ono Pharmaceutical Enter Into A Clinical Collaboration Agreement

Schrödinger Gets Milestone Payment From Ono

Forty Seven & Ono Pharmaceutical Co Sign Regional License Agreement

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About ONO PHARMACEUTICAL CO., LTD.

ONO PHARMACEUTICAL CO., LTD. is a Japan-based company primarily engaged in the manufacture and sale of pharmaceuticals. The Company operates in one business segment. The Pharmaceutical segment involves in the manufacture and sale of drugs for medical and general use. The Company also involves in the clinical development, introduction and derivation of pharmaceuticals.

Industry

Biotechnology & Drugs

Contact Info

1-8-2, Kyutaro-machi, Chuo-ku

+81.6.62635670

https://www.ono.co.jp/

Executive Leadership

Gyo Sagara

President, Representative Director

Hiroshi Awata

Executive Vice President, Chief Director of Development, Director

Kei Sano

Senior Managing Executive Officer, Chief Director of Business Administration, Director of Product Strategy, Director

Hiroshi Ichikawa

Managing Executive Officer, Chief Director of Sales, Senior Director of Primary

Kazuhito Kawabata

Managing Executive Officer, Chief Director of Reliability Assurance, Director

Key Stats

2.69 mean rating - 13 analysts
Sell
Hold
Buy
Revenue (MM, JPY)

2017

0.2K

2018

0.3K

2019

0.3K

2020(E)

0.3K
EPS (JPY)

2017

105.270

2018

97.000

2019

100.250

2020(E)

110.942
Price To Earnings (TTM)
22.44
Price To Sales (TTM)
4.40
Price To Book (MRQ)
2.22
Price To Cash Flow (TTM)
18.96
Total Debt To Equity (MRQ)
1.60
LT Debt To Equity (MRQ)
1.21
Return on Investment (TTM)
9.82
Return on Equity (TTM)
8.69

Latest News

Latest News

Nikkei rises to new 27-year high as earnings hopes underpin mood; Ono Pharma soars

Japan's Nikkei advanced to a fresh 27-year high on Tuesday as stronger earnings hopes underpinned sentiment, while Ono Pharmaceutical jumped on news that a Nobel Prize was awarded to researchers for a cancer-fighting method used in its drug Opdivo.

Ono Pharma shares soar; Nobel awarded for cancer-fighting method used in its drug

Shares of Ono Pharmaceutical Co jumped to levels not seen in over two years after a Nobel Prize was awarded to researchers for a cancer-fighting method used in Opdivo, a drug it co-developed with Bristol-Myers Squibb Co.

Ono Pharma shares soar; Nobel awarded for cancer-fighting method used in its drug

Shares of Ono Pharmaceutical Co <4528.T> jumped to levels not seen in over two years after a Nobel Prize was awarded to researchers for a cancer-fighting method used in Opdivo, a drug it co-developed with Bristol-Myers Squibb Co <BMY.N>.

Ono Pharma shares soar; Nobel awarded for cancer-fighting method used in its drug

Shares of Ono Pharmaceutical Co jumped to levels not seen in over two years after a Nobel Prize was awarded to researchers for a cancer-fighting method used in Opdivo, a drug it co-developed with Bristol-Myers Squibb Co.

BRIEF-Merus Says Ono Pharma Exercised Option For New Research And License Agreement

* MERUS ANNOUNCES ONO PHARMACEUTICALS EXERCISE OF ITS OPTION FOR NEW RESEARCH AND LICENSE AGREEMENT TO GENERATE BISPECIFIC ANTIBODY TARGETING AUTOIMMUNE DISEASES

BRIEF-Ono Pharmaceutical enters into license agreement with Bristol-Myers Squibb for Prostaglandin E2 receptor antagonists

* Says it entered into license agreement with Bristol-Myers Squibb Company (BMS)for Prostaglandin E2 receptor antagonists relating to Immuno-Oncology programs

BRIEF-Bristol-Myers Squibb Granted Exclusive License By Ono Pharmaceutical For Multiple Programs Targeting Immuno-Suppressive Factors In The Tumor Microenvironment

* BRISTOL-MYERS SQUIBB GRANTED EXCLUSIVE LICENSE BY ONO PHARMACEUTICAL FOR MULTIPLE PROGRAMS TARGETING IMMUNO-SUPPRESSIVE FACTORS IN THE TUMOR MICROENVIRONMENT

BRIEF-Ono Pharmaceutical completes retirement of treasury shares

* Says it completed retirement of 45.9 million shares (7.8 percent of outstanding) on Oct. 31

BRIEF-Karyopharm and Ono Pharmaceutical sign exclusive license agreement to develop and commercialize Selinexor and KPT-8602 in Japan and other countries in Asia

* Karyopharm and Ono Pharmaceutical Co. Ltd. sign exclusive license agreement to develop and commercialize Selinexor and KPT-8602 in Japan and other countries in Asia

BRIEF- Ono Pharmaceutical completes share repurchase

* Says it completes repurchase of 15.9 million shares of its common stock, for 38.77 billion yen in total, from June 14 to Sept. 29

BRIEF-Array Biopharma reports Q4 loss per share $0.17

* Array Biopharma reports financial results for the fourth quarter and full year of fiscal 2017

BRIEF-OncoTherapy Science says close of peptide vaccine related agreement with ONO PHARMACEUTICAL

* Says peptide vaccine related agreement with ONO PHARMACEUTICAL CO., LTD. will close on Sept. 4

Nikkei edges down ahead of Fed; Nintendo, Ono Pharma outperform

Japanese stocks ended marginally lower in choppy trade on Wednesday, as investors refrained from taking positions ahead of the U.S. Federal Reserve's monetary policy decision.

BRIEF- Ono Pharmaceutical to repurchase and retire shares

* Says it will repurchase up to 20 million shares, representing 3.8 percent of outstanding

BRIEF-Ono Pharmaceutical concludes a license agreement with array biopharma related to MEK inhibitor and BRAF inhibitor

* Says it concluded a license agreement with Array Biopharma Inc. to develop and commercialize binimetinib, a MEK inhibitor and encorafenib, a BRAF inhibitor, in Japan and South Korea.

BRIEF-Array Biopharma & Ono Pharmaceutical announce partnership for two Novel Oncology compounds

* Array Biopharma & Ono Pharmaceutical Co Ltd announce license, development & commercialization partnership for 2 Novel Oncology compounds, Binimetinib and Encorafenib

BRIEF- Ono Pharmaceutical signs co-development and marketing collaboration agreement with Seikagaku

* Says Seikagaku Corp and Ono Pharmaceutical Co., Ltd. have reached a basic agreement related toco-development and marketing collaboration on SI-613 under development by Seikagaku for the treatment of osteoarthritis in Japan

BRIEF-Ono pharmaceutical plans to spend $3.55 bln to $4.44 bln on acquisitions in the U.S. over next 5 years - Nikkei

* Ono Pharmaceutical plans to spend 400 billion Yen to 500 billion yen ($3.55 billion to $4.44 billion) on acquisitions in the U.S. over next five years - Nikkei Source text for Eikon: Further company coverage:

BRIEF-Ono Pharmaceutical reaches settlement with Merck and signs license agreement

* Says the co and BMS reached settlement and signed license agreement with Merck for patent infringement lawsuit against Merck, regarding anti-PD-1 antibody

Merck, Bristol-Myers agree to settle Keytruda patent suit

Merck & Co said it agreed to enter into a settlement and license agreement with Bristol-Myers Squibb Co and Ono Pharmaceutical Co Ltd to resolve all global patent-infringement litigation related to its cancer drug, Keytruda.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up